Eliem Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 45.24 million compared to USD 47.48 million a year ago. Basic loss per share from continuing operations was USD 1.72 compared to USD 4.24 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.605 USD | -3.61% | +0.26% | +187.78% |
12/06 | Eliem Therapeutics, Inc. Appoints Aoife Brennan as Chief Executive Officer | CI |
12/06 | Eliem Therapeutics, Inc. Announces Management Changes | CI |
1st Jan change | Capi. | |
---|---|---|
+187.78% | 235M | |
+16.38% | 122B | |
+19.94% | 115B | |
+21.22% | 26.64B | |
-23.31% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-18.88% | 15.49B | |
+61.62% | 14.83B | |
+3.38% | 13.67B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Eliem Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022